Screener
Maze Therapeutics MAZE EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Maze Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:48 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344903
FAQ
- What is Maze Therapeutics's EPS (diluted)?
- Maze Therapeutics (MAZE) reported EPS (diluted) of -$0.76 in Q2 2026.
- How has Maze Therapeutics's EPS (diluted) changed year-over-year?
- Maze Therapeutics's EPS (diluted) increased by 1.3% year-over-year, from -$0.77 to -$0.76.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Maze Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude